{"id":"W2716435817","doi":"10.1200/jco.2017.35.15_suppl.tps2082","title":"Clinical trials of VAL-083 in patients with chemo-resistant glioblastoma.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Delmar (Canada)","funders":"","keywords":"Temozolomide; Medicine; Bevacizumab; Lomustine; Oncology; Internal medicine; Phases of clinical research; Glioma; Dacarbazine; Regimen; Clinical trial; Cancer; Chemotherapy; Cancer research; Cyclophosphamide; Vincristine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001078089,0.001277591,0.001413963,0.0005245424,0.000357227,0.0006673161,0.0007750128,0.001160306,0.006510633],"category_scores_gemma":[0.000642047,0.0003719598,0.0008332466,0.0006489562,0.0005831014,0.0006441726,0.0003911708,0.002309373,0.001520802],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008520595,"about_ca_system_score_gemma":0.001655746,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001172079,"about_ca_topic_score_gemma":0.003276262,"domain_scores_codex":[0.9997404,0.0001231827,0.00002171237,0.00003575531,0.0000214554,0.00005749918],"domain_scores_gemma":[0.9996032,0.00003963289,0.00007894912,0.00002567301,0.00003374685,0.0002187508],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6695641,0.02547631,0.005742672,0.001917514,0.001258394,0.0004494531,0.0002857197,0.001675622,0.0381345,0.0006872872,0.01276497,0.2420434],"study_design_scores_gemma":[0.5395604,0.4295093,0.01223388,0.0001327613,0.000493394,0.0006549815,0.00009572782,0.0009917415,0.003788173,0.0007177478,0.0117849,0.00003694503],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9763147,0.006760221,0.0005394552,0.001869564,0.0003363076,0.005026871,0.002467506,0.0002929129,0.006392445],"genre_scores_gemma":[0.9749921,0.004684081,0.001680517,0.002586524,0.0001712694,0.006372493,0.004816642,0.00004917167,0.004647095],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006510633,"threshold_uncertainty_score":0.02178025,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2068326770256303,"score_gpt":0.5357028246284492,"score_spread":0.328870147602819,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}